89 related articles for article (PubMed ID: 22402426)
1. Abiraterone: current and future use in prostate cancer.
Ryan CJ
Clin Adv Hematol Oncol; 2012 Mar; 10(3):180-1. PubMed ID: 22402426
[No Abstract] [Full Text] [Related]
2. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone. Cougar Biotechnology.
Madan RA; Arlen PM
IDrugs; 2006 Jan; 9(1):49-55. PubMed ID: 16374734
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone and MVD3100 take androgen deprivation to a new level.
Schmidt C
J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
[No Abstract] [Full Text] [Related]
5. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
6. Durable complete remission with abiraterone in castration resistant metastatic prostate cancer.
Shah BK; Shrestha S
Acta Oncol; 2013 Jan; 52(1):174. PubMed ID: 23121012
[No Abstract] [Full Text] [Related]
7. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.
Beckett RD; Rodeffer KM; Snodgrass R
Ann Pharmacother; 2012; 46(7-8):1016-24. PubMed ID: 22714819
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone in prostate cancer.
Ryan C
Clin Adv Hematol Oncol; 2010 Nov; 8(11):761-2. PubMed ID: 21326154
[No Abstract] [Full Text] [Related]
9. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Takeda M; Hosaka M
Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
[No Abstract] [Full Text] [Related]
10. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer: score one for validated targets.
Bates SE
Clin Cancer Res; 2011 Jun; 17(12):3866. PubMed ID: 21680541
[No Abstract] [Full Text] [Related]
12. Abiraterone acetate for castration resistant prostate cancer.
Shah S; Ryan C
Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
[TBL] [Abstract][Full Text] [Related]
13. Cancer expert doubts claims about prostate cancer trial.
Cole A
BMJ; 2008 Jul; 337():a979. PubMed ID: 18653636
[No Abstract] [Full Text] [Related]
14. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
Moul JW
BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
[No Abstract] [Full Text] [Related]
15. Use of abiraterone for prostate cancer.
Mohler JL; Pantuck AJ
J Urol; 2011 Mar; 185(3):783-6. PubMed ID: 21239011
[No Abstract] [Full Text] [Related]
16. [Hormonal treatment of cancer of the prostate: review and present status].
Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
[No Abstract] [Full Text] [Related]
17. Therapies in development for castrate-resistant prostate cancer.
Harzstark AL; Ryan CJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
[TBL] [Abstract][Full Text] [Related]
18. [Current strategies of intermittent hormone therapy in prostate cancer].
Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
[TBL] [Abstract][Full Text] [Related]
19. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
Bryce A; Ryan CJ
Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
[TBL] [Abstract][Full Text] [Related]
20. NICE recommends abiraterone for prostate cancer after manufacturer reduces price.
Kmietowicz Z
BMJ; 2012 May; 344():e3520. PubMed ID: 22611169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
